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A B S T R A C T
Objective: Oxylipins are biologically active signaling molecules that initiate and resolve inﬂammation; they are
synthesized by oxidation of polyunsaturated fatty acids (PUFAs) and reﬂect PUFA intake and status. The PUFA
intake in preterm infants diﬀers between countries because of the type of lipid emulsions used and the PUFA
content of breast milk. We compared total blood PUFA, free PUFA and their oxylipin levels in dried whole blood
samples from preterm infants born in Australia and Japan.
Methods: We enrolled 30 and 14 preterm infants born less than 31 weeks’ gestation, from Adelaide and Japan
respectively. Blood samples were obtained from cord blood, and on postnatal days 4, 7, 14 and 28. Total PUFAs
were measured using gas chromatography, while free fatty acids and oxylipins were screened using ultra high-
performance liquid chromatography mass spectroscopy.
Results: Diﬀerences in the levels of blood PUFA between the centres were found which were in line with the
timing and type of lipid emulsion administration. Signiﬁcant diﬀerences in longitudinal levels were seen more
often in free PUFA and their oxylipins than in total blood PUFA. This was particularly true for AA and DHA. In
contrast, diﬀerences in the levels could be seen in total blood EPA, as well as in free EPA and its oxylipins.
Further, levels of many free PUFA and their oxylipins were higher in Japanese infants than in Australian infants.
Conclusion: Diﬀerences in total and free fatty acids and unesteriﬁed oxylipins, were observed during the ﬁrst
weeks of life and between preterm infants born in Australia and Japan, which were likely a reﬂection of the type
of lipid emulsion and timing of administration. The clinical signiﬁcance of these changes remains to be explored.
1. Introduction
Very preterm infants (<32 weeks' gestation) frequently receive
parenteral nutrition which is progressively replaced by an increasing
enteral intake (breast milk and/or formula) as they transition to full
enteral feeding. The fats of both sources of nutrition contain a range of
fatty acids including the essential polyunsaturated fatty acids (PUFA),
including the omega-6 linoleic acid (LA) and the omega-3 alpha lino-
lenic acid (ALA), as well as their long chain PUFA metabolites arachi-
donic acid (AA - an omega-6 derivative), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), both omega-3 derivatives.
The majority of fats in the circulation, whether derived from tissue
sources, the diet or administered intravenously, exist esteriﬁed into
triglycerides, phospholipids or cholesteryl esters. In response to various
https://doi.org/10.1016/j.plefa.2019.102026
Received 14 August 2019; Received in revised form 29 October 2019; Accepted 5 November 2019
Abbreviations: AA, arachidonic acid; ALA, linolenic acid; CI, conﬁdence intervals; DBS, dried blood spot; DHA, docosahexaenoic acid; DiHOME, dihydroxy-
octadecenoic acid; EET, epoxy-eicosatrienoic acid; EPA, eicosapentaenoic acid; EpDPA, epoxy docosapentaenoic acid; EpHOME, epoxy-hydroxy-octadecenoic acid;
FAME, fatty acid methyl esters; FFA, free fatty acid; FID, ﬂame ionisation detector; GMR, ratio of geometric means; HDHA, hydroxy-docosahexaenoic acid; HEPE,
hydroxy-eicosapentaenoic acid; HETE, hydroxy-eicosatetraenoic acid; HODE, hydroxy-octadecadienoic acid; HOTrE, hydroxy-octadecatrienoic acid; IQR, inter-
quartile range; JSH, Juntendo Shizuoka Hospital, Shizuoka Prefecture, Japan; LA, linoleic acid; LTB4, leukotriene B4; LX, lipoxin; oxo-ODE, oxo-octadecadienoic
acid; PUFA, polyunsaturated fatty acids; WCH, Women's and Children's Hospital, Adelaide, Australia
⁎ Corresponding author at: School of Agriculture Food and Wine, The University of Adelaide, PMB 1, Glen Osmond, SA 5064, Australia.
E-mail address: robert.gibson@adelaide.edu.au (R.A. Gibson).
Prostaglandins, Leukotrienes and Essential Fatty Acids xxx (xxxx) xxxx
0952-3278/ © 2019 Elsevier Ltd. All rights reserved.
Please cite this article as: Hiroki Suganuma, et al., Prostaglandins, Leukotrienes and Essential Fatty Acids, 
https://doi.org/10.1016/j.plefa.2019.102026
medical and physiological stressors, diverse lipases cause the release of
free fatty acids (FFA) from these stores. In the case of the PUFA, their
FFA can subsequently be oxidized via enzymatic processes (lipox-
ygenase, cyclooxygenase and cytochrome P450) or via non-enzymatic
free radical oxidation to produce a variety of biologically active mole-
cules known as oxylipins [1]. These oxylipins play important roles with
respect to inﬂammation and its resolution, platelet aggregation, vaso-
dilatation and tissue repair processes [2-4].
Studies in adults have reported that oxylipins derived from LA may
be related to inﬂammatory disorders [5-9]. The subsequent demon-
stration that a reduction in dietary LA resulted in a reduction in levels
of these LA-derived oxylipins, and an improvement in clinical signs,
supports a role of these oxylipins in the pathogenesis of some disease
states, for e.g. atherosclerosis [10]. Conversely, in a neonatal animal
model of hyperoxia-induced lung disease, DHA and AA derived oxyli-
pins markedly reduced lung injury, suggesting there may be a ther-
apeutic role for selected oxylipins in ameliorating neonatal lung disease
[11]. High levels of anti-inﬂammatory and pro-resolving oxylipins were
recently detected in human milk, suggesting a role in gut function and
immunity in the newborn [12].
PUFA are crucial nutrients in preterm infants and are important for
normal development of the central nervous system, with DHA playing
important roles in cognitive and visual development [13]. The PUFA
intake in very preterm infants may diﬀer between countries because of
the diﬀerent types of intravenous lipid emulsions administered and
intrinsic diﬀerences in the PUFA proﬁles of breast milk. In Australia,
very preterm infants typically receive SMOFlipid® (Fresenius Kabi,
Uppsala, Sweden) made from a combination of soy oil, medium-chain
triglycerides, olive oil and ﬁsh oil [14]. By contrast, very preterm in-
fants born in Japan typically receive a soy oil-based lipid emulsion
(Intralipos®, Ohtsuka Pharmaceutical, Tokyo, Japan). Japanese infants
may therefore receive higher intakes of LA during the parenteral phase
of nutrition, while Australian infants receive higher amounts of EPA
and DHA. Furthermore, the PUFA proﬁles of breast milk diﬀer between
countries due to diﬀerences in the maternal diet [15, 16]. However, no
published studies have assessed the impact of diﬀerences in the com-
bined parenteral/enteral intake of PUFA on FFA and oxylipin levels in
very preterm infants. Given the known biological activity of these
compounds we aimed to determine whole blood PUFA, omega-6 and
omega-3 derived FFA and oxylipin levels in very preterm infants born in
Australia and Japan, and to explore the relationship between fat intake,
FFA and oxylipin levels.
2. Methods
2.1. Study setting
This study was conducted at the Women's and Children's Hospital
(WCH) (Adelaide, Australia) and the Juntendo Shizuoka Hospital (JSH)
(Shizuoka Prefecture, Japan). The study protocols were approved by
the Human Research Ethics Committee of each institute (WCH: HREC/
17/WCHN/16, JSH: 29.179).
Preterm infants born less than 31 weeks’ gestation were eligible for
inclusion. Infants with suspected metabolic disease, major congenital or
chromosomal abnormality were excluded. A cord blood sample was
collected at birth in all eligible infants. Investigators then approached
parents within 4 days of birth, and written informed consent was ob-
tained; cord blood samples of infants whose families did not consent to
participate were discarded.
2.2. Sample collection
Blood samples (two drops of whole blood) were collected at birth
(cord blood), and on postnatal days 4, 7, 14 and 28 (via heel prick) and
spotted on PUFAcoat® cards [17]. Breast milk samples were collected
on postnatal days 7, 14 and 28. and spotted on to PUFAcoat® cards.
Infants receiving continuous or intermittent tube feeds, or bottle feeds
had two drops of breast milk taken directly from the tubing or bottle.
For those breast feeding at the time of sample collection women were
asked to express two drops of milk directly onto the PUFAcoat® card.
All samples were air dried on a drying rack at room temperature for at
least 3 h and stored at −20 °C until analysis.
2.3. Laboratory analysis
All fatty acid analyses were undertaken in the fatty acid laboratory
at the School of Agriculture Food and Wine, The University of Adelaide.
Thirty-two oxylipins (Supplementary Table 1) and 5 total and FFA
(LA, AA, ALA, EPA and DHA) were screened in whole blood and breast
milk.
2.3.1. Analysis of oxylipin and free fatty acid levels
We used ultra-high performance liquid chromatography (Agilent
1290 Inﬁnity, Agilent Technologies, CA, USA) equipped with tandem
mass spectrometry (Triple Quad 5500 system, AB SCIEX, MA, USA) [18,
19] to screen oxylipins and FFA. Brieﬂy, a 6mm disc of blood was
obtained from the dried blood PUFAcoat® card and placed into a 96-
well plate with extraction solvent (150 µL of 80% aqueous methanol)
containing internal standards (0.1 ng/µL of d5-DHA and d8-AA;
0.05 ng/µL d5-EPA; 0.7 ng/µL of d5-ALA; 1 ng/µL of d4-LA; 0.01 ng/µL
of d8-12S- hydroxy‑eicosatetraenoic acid (HETE), d4- leukotriene B4
(LTB4) and d4-13S- hydroxy‑octadecadienoic acid (HODE)). The plate
was covered and gently shaken on a plate shaker for 30 min at room
temperature. The extraction from each well was transferred to a fresh
well in a new plate, sealed and placed in the ultra-high performance
liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS)
system. Analytes were captured using multiple reaction monitoring
conditions of target parent and product ion as previously described [18,
19].
2.3.2. Total fatty acid analysis
Total fatty acids in the blood and breast milk were measured using
dried blood and milk spot methods [17, 20]. Brieﬂy, the dried blood/
milk spot was added to 2mL of 1% (v/v) H2SO4 (18M AR grade, BDH,
Sussex, UK) in anhydrous methanol (Merck, Darmstadt, Germany) in a
6mL scintillation vial (Wheaton, Millville, USA), and heated at 70 °C for
3 h. The resultant fatty acid methyl esters (FAME) were extracted into
heptanes (Merck, Darmstadt, Germany). FAME were separated and
quantiﬁed using a gas chromatograph (Hewlett-Packard 6890; Palo
Alto, CA, USA) equipped with a BPX70 capillary column 30m x
0.25mm, ﬁlm thickness 0.25 µm (Trajan Scientiﬁc and Medical Pty
Ltd., Victoria, Australia), programmed temperature vaporisation in-
jector and a ﬂame ionisation detector (FID). The injector temperature
was set at 250 °C and the FID temperature at 300 °C. A programmed
temperature ramp (140–240 °C) was used. Helium gas was used as a
carrier at a ﬂow rate of 1mL/min in the column, and the inlet split ratio
was set at 20:1. The identiﬁcation and quantiﬁcation of FAME were
achieved by comparing the retention times and peak area values of
unknown samples to those of commercial lipid standards (GLC-463, Nu-
Chek Prep Inc., Elysian, MN, USA) using the Agilent Chemstation data
system.
2.4. Nutritional management and data collection
The nutritional management approach for each unit is presented in
Supplementary Table 2. Both centres aimed to commence total par-
enteral nutrition (glucose, amino acids, electrolytes and trace elements)
within the ﬁrst 24 h. The parenteral lipid emulsion used at the WCH
was 20% SMOFlipid® containing 30% soybean oil, 30% medium-chain
triglycerides, 25% olive and 15% ﬁsh oil in water consisting of LA, AA,
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ALA, EPA and DHA of 37.2, 1, 4.7, 4.7 and 4.4% (by wgt of total fatty
acids) respectively [14], whereas JSH used 20% Intralipos® containing
100% soybean oil in water consisting of LA and ALA of 53 and 7% (by
wgt of total fatty acids) respectively but without EPA or DHA (pers
comm. manufacturer). At the WCH enteral feeding was initiated once
expressed breast milk was available (typically day 2) and in the JSH
before 24 h of age. In both institutions feeds are increased at 10–20mL/
kg/d to a total of 150–160mL/kg/d, with parenteral nutrition de-
creasing as enteral intake increased; if breast milk was unavailable then
a preterm formula is used (currently Aptamil Gold+ Preterm, Nutricia,
WCH and GP-P®, Morinaga Milk Industry Co., Ltd, Tokyo, Japan, JSH).
Human milk is fortiﬁed at the WCH when tolerating an enteral intake of
approximately 100mL/kg/d and at the JSH when tolerating 80mL/kg/
d. The fortiﬁers in use during this study did not contain PUFA. Infant
clinical and intake data were collected from medical charts.
2.5. PUFA intake calculations
The PUFA (LA, AA, ALA, EPA and DHA) content of parenteral lipid
emulsions and infant formula was based on the manufacture's in-
formation. The enteral PUFA (LA, AA, ALA, EPA and DHA) intake from
breast milk was determined from the PUFA proﬁles of collected breast
milk samples (Supplementary Table 3) assuming a milk lipid con-
centration of 3.5% [21]. The average breast milk concentration of the
group (WCH or JSH) was used for each speciﬁc timepoint if an in-
dividual breast milk sample was not available for the corresponding
time point. The total PUFA intake was calculated for the 24 h prior to
the time (day) of the blood sample collection.
2.6. Statistical analysis
Diﬀerences in maternal and infant characteristics between the
groups were determined using Mann-Whitney U tests or t tests for
continuous variables and Fisher's exact tests for categorical variables.
Linear mixed eﬀects models were used to estimate diﬀerences in mean
oxylipin, FFA and PUFA levels in the blood between the recruiting
centres across time with recruiting centre, sampling time and the in-
teraction between centre and time included as ﬁxed eﬀects and infant
included as a random eﬀect. The interaction term was excluded when
the global test was not statistically signiﬁcant (p≥ 0.05) and instead
comparisons were made between recruiting centres across all time
points. When model residuals were not normally distributed, outcome
data were log transformed and diﬀerences between centres were in-
stead expressed as ratios of geometric means with 95% conﬁdence in-
tervals (CIs). In exploratory analyses, a separate multiple linear re-
gression was performed to estimate associations of each PUFA intake
(parenteral and enteral) with FFA and their related oxylipins at each
time point. The following variables thought to inﬂuence oxylipin levels
were included in the model: total PUFA intake at postnatal day 4, 7, 14,
28, sex, gestational age and antenatal corticosteroid therapy. Oxylipin
data were log-transformed to approximate normality and estimates
(beta-coeﬃcients) were back-transformed to estimate the geometric
mean ratio (GMR) with 95% CI. A p value of < 0.05 was considered
statistically signiﬁcant. All statistical analyses were performed using
SPSS for Windows version 25.0 software (IBM, Armonk, NY, USA) and
the software package R (version 3.5.1, R Foundation for Statistical
Computing).
3. Results
3.1. Characteristics of the study population
This was an opportunistic study with recruitment occurring between
September 2017 and March 2018 at the WCH and May 2017 and March
2018 at the JSH. During this time ﬁfty-one infants (36 WCH and 15
JSH) were eligible, 45 were enrolled, and 44 were included in the
analysis (30 infants WCH and 14 infants JSH). One infant from the
WCH was excluded from analysis due to long-chain 3-hydroxyacylCoA
dehydrogenase deﬁciency [22].
Relative to the WCH cohort, mothers of infants from the JSH were
older and leaner, their infants’ birthweight was less and duration of
respiratory support longer. More JSH infants required oxygen at 36
weeks postmenstrual age and developed retinopathy of prematurity
than the WCH infants (Table 1). JSH infants commenced enteral
feeding earlier than WCH infants, however the WCH infants achieved
full enteral feeding almost one week earlier than the JSH infants
(Table 2). Total parenteral nutrition was commenced earlier in JSH
than WCH (JSH median 0.5, interquartile range (IQR) 0 - 1.3 h, WCH
median 7.5, IQR 2 - 14.3 h) whereas lipid emulsion was commenced
later (JSH median 92, IQR 68 - 121 h, WCH median 17, IQR 11.2 -
25.5 h); there were no diﬀerences in number of days of total parenteral
nutrition or lipid emulsion between the hospitals. All infants received at
least some breast milk.
3.2. PUFA intake
The PUFA intake (LA, AA, ALA, EPA and DHA) from both parenteral
lipid emulsion and enteral feeding at each time point are shown in
Figs. 1-5 (see Supplementary Table 3 for breast milk PUFA proﬁle).
Total LA, AA, ALA, EPA and DHA intakes on day 4 and 7 were higher in
WCH infants compared with JSH infants. There were no signiﬁcant
diﬀerences in PUFA intake between the groups on days 14 and 28.
3.3. Longitudinal changes in total blood PUFA, FFA and their metabolites
3.3.1. Total whole blood omega-6 LA, free LA and LA derived oxylipin
Total LA in both groups gradually increased to more than double by
postnatal day 28 compared with the cord blood samples (Fig. 1a,
Supplementary Table 4). Although total LA at day 4 in WCH infants
was signiﬁcantly higher compared with JSH infants, this was reversed
by day 14. Free LA was also signiﬁcantly higher in the WCH infants at
Table 1
Maternal and infant characteristicsa.
WCH (n=30) JSH (n=14) p-values
Maternal characteristics
Age, median (IQR) years 30 (26–33) 36 (32–38) <0.01
BMI, median (IQR) 26.9
(22.8–28.4)
20.0
(18.8–32.5)
0.03
Chorioamnionitis 10 (33) 5 (36) 1.00
Cesarean delivery 21 (70) 13 (93) 0.13
Received antenatal
corticosteroids
26 (87) 9 (64) 0.03
Infant characteristics
Gestational age, median (IQR)
weeks
29 (28–30) 27 (25–29) 0.09
Birth weight, median (IQR)
grams
1260
(930–1546)
829 (653–992) <0.01
Ponderal index, median (IQR) 22.0
(20.6–23.8)
23.5
(20.3–27.9)
0.35
Male sex 11 (37) 5 (36) 1.00
Multiple birth (no. of infants) 13 (43) 1 (7) 0.08
Apgar score ≤7 at 5 min 12 (40) 7 (50) 0.75
Oxygen treatment at 36 weeks 7 (23) 9 (64) 0.02
Respiratory (oxygen/airway)
support, median (IQR) days
6 (2–34) 63 (35–96) <0.01
Postnatal steroids 6 (20) 8 (57) 0.03
Sepsis 4 (13) 0 0.29
Necrotizing enterocolitis 1 (3) 0 1.00
Intraventricular hemorrhage 4 (13) 2 (14) 1.00
Retinopathy of prematurity 4 (13) 9 (64) <0.01
Death 2 (7) 0 1.00
Abbreviations : JSH, Juntendo Shizuoka Hospital, Shizuoka Prefecture, Japan;
WCH, Women's and Children's Hospital, Adelaide, Australia.
a Data are presented as n (%) unless otherwise indicated.
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Table 2
Nutritional managementa.
WCH (n=30) JSH (n=14) p-values
Age enteral feeds commenced (hrs) 23 (15–47) 9 (7–19) <0.01
Age full enteral feeding achievedb (days) 9 (7–13) 15.5 (13–19) <0.01
Received parenteral lipid emulsion, n (%) 22 (73)c 11 (79)d 1.00
Age parenteral lipid emulsion commenced (hrs) 17 (11–26) 92 (68–121) <0.01
Duration of parenteral lipid emulsion (days) 8 (5–11) 5 (4–9) 0.14
Received total parenteral nutrition, n (%) 22 (73) 14 (100) 0.04
Age total parenteral nutrition commenced (hrs) 8 (2–14) 1 (0–1) <0.01
Duration of total parenteral nutrition (days) 11 (6–15) 14 (10–17) 0.22
Abbreviations : JSH, Juntendo Shizuoka Hospital, Shizuoka Prefecture, Japan; WCH, Women's and Children's Hospital, Adelaide, Australia.
a Data are presented as median (interquartile range) unless otherwise indicated.
b
Enteral intake of > 120mL/kg/d and maintained for three days.
c
All received SMOFlipid®.
d
All received Intralipos®.
Fig. 1. n-6 LA and metabolites in preterm infants born in Australia (WCH) and Japan (JSH). (1a), Estimated geometric mean (solid line) and 95% conﬁdence interval
(shaded area) for LA, free LA and LA derived metabolites (oxylipins) in cord blood and on postnatal days 4, 7, 14 and 28. The data were log-transformed for analysis
unless otherwise indicated. A statistically signiﬁcant interaction eﬀect between hospital and time was found in LA, free LA and all LA derived oxylipins, where
comparisons between recruiting centres at each time point were made. (1b), Mean intake of LA (error bars represent standard deviation) on postnatal days 4, 7, 14
and 28.
a data were not log-transformed
* p < 0.05; ** p < 0.01, WCH vs. JSH at each time point.
LA, linoleic acid; EpHOME, epoxy‑hydroxy‑octadecenoic acid; oxo-ODE, oxo-octadecadienoic acid; HODE, hydroxy‑octadecadienoic acid; DiHOME, dihydroxy-
octadecenoic acid.
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Fig. 2. n-6 AA and metabolites in preterm infants born in Australia (WCH) and Japan (JSH) (2a), Estimated geometric mean (solid line) and 95% conﬁdence intervals
(shaded area) for AA, free AA and AA derived metabolites (oxylipins) in cord blood and on postnatal days 4, 7, 14 and 28. The data were log-transformed for analysis
unless otherwise indicated. A statistically signiﬁcant interaction eﬀect between hospital and time was found in AA, free AA and 7 AA derived oxylipins (8- HETE, 9-
HETE, 11- HETE 12- HETE, 15- HETE, 8,9-EET, 14, 15-EET), where comparisons between recruiting centres at each time point were made. For the remaining AA
derived oxylipins, an overall comparison between recruiting centres across all time points was reported (indicated on the right with statistical signiﬁcance shown as
described below). (2b), Mean intake of AA (error bars represent standard deviation) on postnatal days 4, 7, 14 and 28.
a data were not log-transformed
* p < 0.05; ** p < 0.01, WCH vs. JSH at each time point.
AA, arachidonic acid; HETE, hydroxy‑eicosatetraenoic acid; EET, epoxy-eicosatrienoic acid; LTB4, leukotriene B4; LX, lipoxin.
H. Suganuma, et al. Prostaglandins, Leukotrienes and Essential Fatty Acids xxx (xxxx) xxxx
5
day 4 compared with the JSH infants, which was reversed by day 7 and
14 (Fig. 1a, Supplementary Table 5).
Four LA-derived oxylipins (epoxy‑hydroxy‑octadecenoic acid (9,10
EpHOME), 9- oxo-octadecadienoic acid (oxo-ODE), 13-HODE and 12,13
dihydroxy-octadecenoic acid (DiHOME)) were detected (Fig. 1a, Sup-
plementary Table 6). At day 4, 9-oxo-ODE and 12,13DiHOME were
signiﬁcantly higher in WCH than JSH infants. By day 7 and beyond the
four LA-derived oxylipins detected were signiﬁcantly higher in JSH
infants compared with WCH infants (Supplementary Table 6).
3.3.2. Total whole blood omega-6 AA, free AA and AA derived oxylipin
Total AA was signiﬁcantly higher in the cord blood of the WCH
group with levels decreasing over time and no diﬀerences were ob-
served between the groups at any time point thereafter (Fig. 2a, Sup-
plementary Table 3). Cord blood free AA levels were signiﬁcantly
higher in WCH infants compared with JSH infants. By day 4 free AA
concentration was higher in JSH infants which was maintained through
day 7 and 14 (Fig. 2a, Supplementary Table 5). Sixteen AA- derived
oxylipins were detected (Fig. 2a, Supplementary Table 6) with 5- and
12- HETE the most abundant. 8-, 11- and 12-HETE were signiﬁcantly
higher in the cord blood of WCH infants than JSH infants. At various
times across days 4 to 28, six AA-derived oxylipins (8-, 9-, 12-, 15-
HETE, 8,9- and 14,15- EET) were signiﬁcantly higher in the JSH infants
compared with the WCH infants.
The JSH infants had overall higher 5-HETE, 11,12-EET, LTB4 and
LXB4 levels compared with the WCH infants (Supplementary Table 6),
and overall lower Prostaglandin F2 levels.
3.3.3. Total whole blood omega-3 ALA, free ALA and ALA derived oxylipin
No diﬀerences in total ALA were found between the groups (Fig. 3a,
Supplementary Table 4). Free ALA levels at day 4 were signiﬁcantly
higher in WCH infants (Fig. 3a, Supplementary Table 5). At day 4,
ALA-derived oxylipin 9- hydroxy-octadecatrienoic acid (HOTrE) was
signiﬁcantly higher in WCH infants compared with JSH infants but by
day 7 this was reversed (Fig. 3a, Supplementary Table6).
3.3.4. Total blood omega-3 EPA, free EPA and EPA derived oxylipin
Total EPA was higher in the cord blood of JSH infants compared
with WCH infants. At day 4 through to day 14 total EPA levels were
signiﬁcantly higher in WCH infants (Fig. 4a, Supplementary Table 4).
Free EPA (Fig. 4a, Supplementary Table 5), and the EPA derived
oxylipin 18- hydroxy‑eicosapentaenoic acid (HEPE), at day 4 and 7
were signiﬁcantly higher in WCH infants compared with JSH infants
(Fig. 4a, Supplementary Table 6).
3.3.5. Total blood omega-3 DHA, free DHA and DHA derived oxylipin
Total cord blood DHA was signiﬁcantly higher in the JSH infants.
Infant DHA levels decreased by around 30% in both groups thereafter
with no signiﬁcant diﬀerences between groups (Fig. 5a, Supplemen-
tary Table 4). Free DHA levels in the JSH infants at day 14 and 28 were
signiﬁcantly higher than those in the WCH infants (Fig. 5a, Supple-
mentary Table 5). Five DHA derived oxylipins were detected (4‑hy-
droxy‑docosahexaenoic acid (HDHA), 7-HDHA, 14-HDHA 16,17EpDPA
and 19,20EpDPA). The DHA derived oxylipin 19,20EpDPA, cord blood,
at day 4 and 7 were signiﬁcantly higher in the JSH infants compared
with the WCH infants (Fig. 5a, Supplementary Table 6). Overall, 4-
HDHA and 16,17EpDPA levels were signiﬁcantly higher in JSH infants
(Fig. 5a, Supplementary Table 6).
3.4. Associations between total PUFA intakes, FFA and oxylipins
On day 4 most of the measured oxylipins and their related FFA were
signiﬁcantly and positively associated with their parent PUFA intakes
(Table 3). The exception was for AA where only one oxylipin (Pros-
taglandin F2) was positively associated AA intake. Signiﬁcant negative
associations were apparent for 5-HETE and EPA and DHA intake
(Table 3); PUFA intake was predominantly parenteral at this time. Most
of the measured FFA and the oxylipins 9-HOTrE, 18-HEPE and 7-HDHA
were positively associated with their parent PUFA intake on day 7
(Table 3). A negative association occurred for 8-, 9-, 12-HETE and
14,15EET with EPA intake at this time. By day 14, signiﬁcant positive
associations were seen between EPA intake and free EPA, and 18-HEPE.
4-HDHA and 19,20EpDPA were positively associated with DHA intake
on day 28; PUFA intake was predominantly enteral at this time.
4. Discussion
We have characterized whole blood PUFA levels and their deriva-
tives (FFA and oxylipins) in preterm infants born <31 weeks’ gestation
during the ﬁrst month of postnatal life from an Australian (WCH) and
Japanese (JSH) neonatal unit. A characteristic of this study is the dif-
ference in clinical practice relating to the type of parenteral lipids used
and the timing of their introduction. Japanese clinicians tend to delay
initiation of parenteral lipids (commencing at ~4 days of age) and use a
preparation composed of vegetable oil. In contrast Australian practice is
to initiate parenteral lipids in the ﬁrst day of life and use a preparation
that is a mixture of MCT oil, vegetable oil and marine oil. This diversity
in practice resulted in clear diﬀerences in the pattern of PUFAs and
their derivatives seen in the blood of the infants.
Despite the diﬀerences in the intake of individual PUFAs, this did
not always translate to diﬀerences in the percent composition of the
PUFAs between the groups. This was particularly true of AA, ALA and
DHA. While small diﬀerences were seen in LA levels, it was only in EPA
that large diﬀerences were seen. In contrast, changes in the levels of all
free PUFA concentrations were clearly visible in the blood spots.
Because it is generally thought that FFA are the direct precursors of
their oxygenated compounds known as oxylipins our results are highly
relevant. This importance is underscored by the close relationship be-
tween the levels of many of the free PUFA and their oxylipins. This is
particularly true for free LA and the 4 oxylipin derivatives known as
oxidized linoleic acid metabolites (OXLAMs) as well as free ALA and
free EPA and their related oxylipins. Some free PUFA levels did not
have a close relationship with the oxylipins we measured including free
AA where only seven of the 16 oxylipins measured followed similar
patterns to the free AA levels, and free DHA where only one of ﬁve
oxylipins seemed to be directly related to free DHA levels.
The changes in LA, ALA and EPA blood concentrations, and their
oxylipin metabolites, were primarily driven by the fatty acid compo-
sition of the parenteral lipid used. LA and ALA were present in both
parenteral lipids used (SMOFlipid® WCH infants, Intralipos® JSH in-
fants), which is why their concentrations peaked in blood upon ad-
ministration, as did concentrations of their oxylipin metabolites.
SMOFlipid® contained EPA, consistent with the rise in blood EPA and
its metabolites in the WCH infants.
Although DHA was present in SMOFlipid® (WCH infants), total DHA
percent composition did not diﬀer signiﬁcantly between the groups
over time. Tissue reserves of DHA are likely higher in Japanese than
Australian infants due to higher maternal intake of DHA by Japanese
women [23]. Hence, supplemental DHA is likely to partition into tissues
of WCH infants, where reserves of DHA and its metabolites are expected
to be lower than Japanese preterm infants.
AA percent composition did not diﬀer over time between the
groups, but free AA and its metabolites (with the exception of pros-
taglandin F2) were lower in preterm infants who received SMOFlipid®
(WCH infants) compared with infants receiving Intralipos® (JSH in-
fants), despite higher intakes of AA in the former, with negative asso-
ciations between some AA derived oxylipins and n-3 PUFA intakes. This
is likely due to displacement of AA from blood by EPA and DHA present
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in SMOFlipid®. Reduced levels of pro-inﬂammatory oxylipins derived
from n-6 PUFAs associated with n-3 PUFA supplementation in an an-
imal model has been described [32], suggesting that n-3 PUFAs may
reduce the release of esteriﬁed AA or the synthesis of AA-derived
oxylipins
A unique feature of this study was that the blood samples were
collected on ﬁlter paper (PUFAcoat® card) as dried blood spots (DBS).
This allowed for the easy collection, transport and storage of samples in
this international study. We have previously reported that our DBS
stabilises the fatty acids in blood for long periods [17] and more re-
cently have reported the utility of our DBS system for the measurement
of free PUFA [18] and their oxylipins [19]. The current study demon-
strates the sensitivity of the DBS system with most free PUFA and many
oxylipins responding to dietary PUFA intake in predictable ways.
Whether the fact that some free PUFA and some oxylipins responded to
dietary PUFA intake while some did not may be due to limitations in the
DBS system and remains to be explored.
Recently, concern has been expressed that high dietary LA intake
Fig. 3. n-3 ALA and metabolites in preterm infants born in Australia (WCH) and Japan (JSH) (3a), Estimated geometric mean (solid line) and 95% conﬁdence
intervals (shaded area) for LA, free LA and LA derived metabolites (oxylipins) in cord blood and on postnatal days 4, 7, 14 and 28. The data were log-transformed for
analysis unless otherwise indicated. A statistically signiﬁcant interaction eﬀect between hospital and time was found in free ALA and ALA derived oxylipins, where
comparisons between recruiting centres at each time point were made. For ALA, an overall comparison between recruiting centres across all time points was reported
(indicated on the right with statistical signiﬁcance shown as described below). (3b), Mean intake of ALA (error bars represent standard deviation) on postnatal days 4,
7, 14 and 28.
* p < 0.05; ** p < 0.01, WCH vs. JSH at each time point.
ALA, α-linolenic acid; HOTrE, hydroxy‑octadecatrienoic acid.
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leads to an increase in levels of the bioactive LA derived oxylipins,
which have been implicated in the pathogenesis of some chronic dis-
eases in adults [23]. In our study, LA derived oxylipins including
9,10EpHOME, 9-oxo-ODE, 13-HODE and 12,13DiHOME were detected.
The diﬀering proportions of PUFA in currently available lipid emulsions
contributes to the blood PUFA proﬁle in preterm infants [24, 25]. In a
systematic review of parenteral lipid emulsion in clinical use showed no
diﬀerences with respect to important clinical outcomes [26]. However,
LA derived oxylipin levels in preterm infants who received lipid
emulsion and the associations between the LA derived oxylipins and LA
intake from lipid emulsion have not been investigated at all. The pre-
sent study indicates that LA intake from lipid emulsion results in an
increase in levels of LA derived oxylipins that may have inﬂammatory
activity. Interestingly, peak levels of LA derived oxylipins in the Japa-
nese infants were more than twice those seen in the Australian infants,
though this was not explained by the intake of LA from lipid emulsion.
In our previous study, Intralipid was shown to contain higher amounts
of LA derived oxylipins compared to SMOFlipid® [27]. It is therefore
likely that diﬀerences in the peak levels of LA derived oxylipins be-
tween the groups are due to the LA derived oxylipins that are ad-
ministered with the lipid emulsions.
The omega-3 PUFA-derived oxylipins have been shown to lead to
anti-inﬂammatory eﬀect in animal models [28]. The EPA derived
oxylipin, 18-HEPE, is the precursor of the anti-inﬂammatory E-resolvin
Fig. 4. n-3 EPA and metabolites in preterm infants born in Australia (WCH) and Japan (JSH) (4a.), Estimated geometric mean (solid line) and 95% conﬁdence
intervals (shaded area) for EPA, free EPA and EPA derived metabolites (oxylipins) in cord blood and on postnatal days 4, 7, 14 and 28. The data were log-transformed
for analysis unless. A statistically signiﬁcant interaction eﬀect between hospital and time was found in EPA, free EPA and EPA derived oxylipins, where comparisons
between recruiting centres at each time point were made. (4b), Mean intake of EPA (error bars represent standard deviation) on postnatal days 4, 7, 14 and 28. * p<
0.05; ** p < 0.01, WCH vs. JSH at each time point.
EPA, eicosapentaenoic acid; HEPE, hydroxy‑eicosapentaenoic acid.
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Fig. 5. n-3 DHA and metabolites in preterm infants born in Australia (WCH) and Japan (JSH) (5a), Estimated geometric mean (solid line) and 95% conﬁdence
intervals (shaded area) for DHA, free DHA and DHA derived metabolites (oxylipins) in cord blood and on postnatal days 4, 7, 14 and 28. The data were log-
transformed for analysis unless otherwise indicated. A statistically signiﬁcant interaction eﬀect between hospital and time was found in DHA, free DHA and 1 DHA
derived oxylipins (19,20-EpDPA), where comparisons between recruiting centres at each time point were made. For the remaining DHA derived oxylipins, an overall
comparison between recruiting centres across all time points was reported (indicated on the right with statistical signiﬁcance shown as described below). (5b), Mean
intake of DHA (error bars represent standard deviation) on postnatal days 4, 7, 14 and 28.
a data was not log-transformed
* p < 0.05; ** p < 0.01, WCH vs. JSH at each time point.
DHA, docosahexaenoic acid; HDHA, hydroxy‑docosahexaenoic acid; EpDPA, epoxy Docosapentaenoic Acid.
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family, which inhibits neutrophil inﬁltration [29] and reduces lipopo-
lysaccharide-triggered TNF-α formation [30]. Furthermore, the DHA
derived oxylipins including HDHA and EpDPA are the precursors of the
resolvin D and protectin D families, which have been shown to have
anti-inﬂammatory eﬀects in a variety of models [4]. Previous studies
demonstrated that n-3 PUFA supplementation containing high DHA and
EPA led to a dose-dependent increase in their derived oxylipins, with an
increase of EPA and DHA of blood cell membrane [31]. In an animal
model, dietary n-3 PUFA supplementation promoted the synthesis of
anti-inﬂammatory oxylipins derived from DHA and EPA in the brain
[32]. Consistent with these studies, we found that the intakes of DHA
and of EPA were positively related to their respective oxylipins.
There have been limited reports of the relationship between preterm
infant inﬂammatory conditions and oxylipins. In preterm infants n-6
PUFA derived oxylipins were not associated with the development of
bronchopulmonary dysplasia [33]. In a neonatal animal model,
downstream DHA and AA derivatives were shown to have the potential
to improve hyperoxia-induced lung injury, speculating that decreases in
DHA and AA in preterm infants after birth leads to a decrease of DHA
and AA derived metabolites potentially contributing to the develop-
ment of lung disease in this population [11]. Furthermore, high levels
of oxylipins have been detected in breast milk which may aﬀect the
immune regulation of the gastrointestinal tract in the newborn
indicating the advantage of human milk [12]. Our current study reports
longitudinal oxylipin levels during the ﬁrst 28 days of life, with dra-
matic changes of LA derived oxylipins from day 4 associated with the
commencement of lipid emulsion.
Oxylipin proﬁles depend on the type of dietary PUFA and the type of
enzymes including lipoxygenase, cyclooxygenase and cytochrome P450
[4]. However, little is known about the association between oxylipin
levels in infants and enteral feeding. In our study enteral DHA and EPA
intake were associated with their oxylipin levels in the blood, while LA
and AA were not. The present study also shows that DHA in breast milk
of Japanese women was approximately two times higher than that of
Australian women. The percentages of n-3 PUFA to total fatty acids in
breast milk, especially DHA, are diﬀerent in each country [15, 34]. It is
likely that those diﬀerences aﬀect their related oxylipins in preterm
infants.
Our study has limitations. Infant characteristics including clinical
treatment, nutrition protocol, disease severity and maternal character-
istics were diﬀerent between the two groups, which may have con-
tributed to the observed diﬀerence in the oxylipin levels. However, the
ﬁndings may reveal that infant environment in each country can result
in the diﬀerences in oxylipin levels, which may aﬀect the clinical out-
comes in preterm infants in each country. As an opportunistic study the
sample size was small which prevented exploration of associations
Table 3
Associations between total PUFA intakes, FFA and oxylipin levels at each time point.
Dependent variables Predictor variables exp(β)a (95% CI) Adjusted R2b p
Day 4 Free LA LA intake 1.003 (1.001–1.004) 0.42 <0.01
9,10 EpHOME LA intake 1.003 (1.001–1.004) 0.35 <0.01
9-Oxoode LA intake 1.003 (1.001–1.004) 0.35 <0.01
13-HODE LA intake 1.002 (1.001–1.004) 0.29 <0.01
12,13DiHOME LA intake 1.003 (1.001–1.005) 0.35 <0.01
5-HETE EPA intake 0.989 (0.978–0.997) 0.14 0.04
5-HETE DHA intake 0.991 (0.983–0.997) 0.14 0.04
Prostaglandin F2 AA intake 1.201 (1.111–1.297) 0.42 <0.01
Free ALA ALA intake 1.040 (1.023–1.057) 0.42 <0.01
9-HOTrE ALA intake 1.022 (1.008–1.037) 0.27 <0.01
Free EPA EPA intake 1.050 (1.036–1.065) 0.62 <0.01
18-HEPE EPA intake 1.047 (1.031–1.063) 0.64 <0.01
Free DHA DHA intake 1.008 (1.002–1.013) 0.43 <0.01
7-HDHA DHA intake 1.010 (1.003–1.017) 0.45 <0.01
14-HDHA DHA intake 1.012 (1.002–1.022) 0.34 0.02
16,17EpDPA DHA intake 1.012 (1.004–1.021) 0.30 <0.01
19,20EpDPA DHA intake 1.008 (1.002–1.015) 0.36 0.01
Day 7 Free LA LA intake 1.001 (1.000–1.002) 0.27 0.01
9,10 EpHOME LA intake 1.001 (1.000–1.002) 0.26 0.03
9-Oxoode LA intake 1.001 (1.000–1.002) 0.20 <0.01
13-HODE LA intake 1.001 (1.000–1.002) 0.30 <0.01
12,13DiHOME LA intake 1.001 (1.000–1.002) 0.19 0.02
8-HETE EPA intake 0.995 (0.991–1.000) 0.20 0.03
9-HETE EPA intake 0.994 (0.989–1.000) 0.25 0.04
12-HETE EPA intake 0.992 (0.986–0.999) 0.20 0.03
12-HETE DHA intake 0.995 (0.990–1.000) 0.20 0.04
14,15EET EPA intake 0.993 (0.987–0.999) 0.14 0.03
Free ALA ALA intake 1.011 (1.004–1.018) 0.25 <0.01
9-HOTrE ALA intake 1.009 (1.002–1.015) 0.23 <0.01
Free EPA EPA intake 1.018 (1.014–1.021) 0.76 <0.01
18-HEPE EPA intake 1.026 (1.019–1.033) 0.57 <0.01
7-HDHA DHA intake 1.005 (1.001–1.009) 0.28 0.01
Day 14 Free EPA EPA intake 1.028 (1.013–1.044) 0.39 <0.01
18-HEPE EPA intake 1.025 (1.005–1.044) 0.24 0.01
Day 28 4-HDHA DHA intake 1.040 (1.006–1.076) 0.23 0.02
19,20EpDPA DHA intake 1.028 (1.005–1.051) 0.33 0.02
Note : Data only shows the statistically signiﬁcant associations between oxylipin as dependent variables and each PUFA intake as predictor variables on each time
point.
Abbreviations : CI, conﬁdential interval; LA, linoleic acid; AA, arachidonic acid; ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid;
EpHOME, epoxy-hydroxy-octadecenoic acid; oxo-ODE, oxo-octadecadienoic acid; HODE, hydroxy-octadecadienoic acid; DiHOME, dihydroxy-octadecenoic acid;
HETE, hydroxy-eicosatetraenoic acid; EET, epoxy-eicosatrienoic acid; HOTrE, hydroxy-octadecatrienoic acid; HEPE, hydroxy-eicosapentaenoic acid; HDHA, hydroxy-
docosahexaenoic acid; EpDPA, epoxy docosapentaenoic Acid.
a exp(β) shown as changes in the ratio of estimated geometric means of the dependent variable.
b
Adjusted for sex, gestational age and antenatal corticosteroid therapy.
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between clinical outcomes and oxylipin levels.
In conclusion, we demonstrated the diﬀerences in the oxylipin levels
between preterm infants born in Australia and Japan. These diﬀerences
were likely a reﬂection of the PUFA concentration in the parenterally
administered lipid emulsion and breast milk. Further studies to in-
vestigate the association between the oxylipin levels and nutrition and
to determine whether oxylipins inﬂuence clinical outcomes in preterm
infants are warranted.
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